Jazz Pharmaceuticals plc

NasdaqGS:JAZZ 주식 보고서

시가총액: US$7.7b

Jazz Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 2/6

Jazz Pharmaceuticals 의 총 주주 지분은 $4.2B 이고 총 부채는 $6.1B, 이는 부채 대 자기자본 비율을 146.6% 로 가져옵니다. 총자산과 총부채는 각각 $12.3B 및 $8.1B 입니다. Jazz Pharmaceuticals 의 EBIT는 $867.6M 이며 이자보상배율은 3.4 입니다. $2.6B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

146.6%

부채 비율

US$6.11b

부채

이자 보상 비율3.4x
현금US$2.62b
주식US$4.17b
총 부채US$8.08b
총 자산US$12.26b

최근 재무 상태 업데이트

Recent updates

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

재무 상태 분석

단기부채: JAZZ 의 단기 자산 ( $4.4B )이 단기 부채( $1.0B ).

장기 부채: JAZZ 의 단기 자산( $4.4B )은 장기 부채( $7.1B ).


부채 대 자본 내역 및 분석

부채 수준: JAZZ 의 순부채 대 자기자본 비율( 83.8% )은 높음으로 간주됩니다.

부채 감소: JAZZ 의 부채 대 자기자본 비율은 지난 5년간 52.6% 에서 146.6% 로 증가했습니다.

부채 범위: JAZZ 의 부채는 영업 현금 흐름 ( 19% )에 의해 잘 갚지 않음입니다.

이자 보장: JAZZ 의 부채에 대한 이자 지급EBIT( 3.4 x 적용 범위)로 잘 충당됩니다.


대차 대조표


건강한 기업 발견하기